Complex scale-up manufacturing capacity and experience have long been central to the manufacturing capabilities at Thermo Fisher Scientific, request for nucleotides and in vitro transcription enzymes, critical raw materials, to support mRNA therapeutics was unprecedented in size, scope, and delivery timeline. To meet the massive increase in raw material supply means enzymes and nucleotides needed to be manufactured at an appropriate scale simultaneously, rather than one by one, as is more common in traditional timelines. Powering this project was 4 key capabilities from Thermo Fisher:
- Network of world-class manufacturing sites staffed with experienced scientists
- Complete portfolio of reagents for mRNA synthesis in regulatory compliance
- Ability to invest in manufacturing sites
- Rapidly mobilize a dedicated project team
Learn how Thermo Fisher Scientific was able to meet the unprecedented need for raw material to support mRNA therapeutics while growing capacity to serve future partnership within the nucleic acid therapeutics. Download the full whitepaper by simply hitting the 'Download Now' link at the top of the page.